Triggered Imaging in Glioblastoma Based on Clinical Outcome Evaluation Compared to Routine: a Feasibility Study

This is a feasibility randomized controlled trial comparing triggered imaging based on patient symptom self-reporting and performance-based measures with the existing imaging schedule.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Glioblastoma Astrocytoma Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

KCH

London, United Kingdom

About this study

Patients in intervention arm will be invited to complete weekly online symptom questionnaires. Responses will be evaluated and given a score, with higher scores reflecting 'red flag' symptoms or symptoms of a severity which meet pre-defined thresholds.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

i. Newly diagnosed glioblastoma (WHO grade IV) ii. Planned to undergo the Stupp treatment regimen iii. Aged 18-70 iv. To be treated at KCH and GSTT v. No MRI contraindications vi. Patients with internet access and an e-mail account

Exclusion criteria

i. Uncertainty of diagnosis ii. Deviation from the standard Stupp regimen iii. Patients participating in another interventional study iv. Unable to read and comprehend English language text v. Lack capacity at point of consent vi. WHO Performance status > 3 (Karnofsky score < 30)

Treatment and study plan

triggered imaging

Diagnostic Test

triggered imaging for symptoms as opposed to routine interval imaging

Primary outcomes

The primary outcomes are: - Number of patients willing to self-report symptoms on an online app - Number of patients willing to undertake cognitive testing - Number of complete symptom questionnaires and assessments - Number of fast track MRI

Time frame: From enrollment up to 12 months
The primary outcomes are: - Number of patients willing to self-report symptoms on an online app - Number of complete symptom questionnaires and assessments - Number of fast track MRI

Time frame: From enrollment up to 12 months

Sponsors and collaborators

Lead sponsor

King's College Hospital NHS Trust

Other

Registry information

Acronym: TIGER F

Important dates

Study start: 2025
Primary completion: 2026
Study completion: 2026
First posted: Jun 9, 2026
Registry last updated: Jun 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting